As of April 1, physicians will be the prescribers of the substance as opposed to Health Canada. In a perfect world, patients will be able to purchase a maximum of 150 grams a month produced by a licensed commercial grow operation. The March 21 injunction that reversed the dictum that all marijuana would be supplied commercially after April 1, will, until a constitutional challenge is heard, allow patients licensed to grow for personal use to continue.
Maintaining the status quo for the time being will certainly ease the transition, application and prescription of cannabis as the new rules settle. In this new world, there are concerns as well as opportunities that will be addressed. Early commercial adopters that are willing to get directly involved in production as the market unfolds will likely see the largest benefits.
Numerous stocks have seen positive reaction to plans to enter the Medical Marijuana market: Windfire Capital was languishing at $0.02 at the beginning of the year and is trading at $0.14 currently, following recent double announcements of closing a private placement and a foray into the Medical Marijuana space.
As well, Affinor has seen its shares rise from under $0.05 March 13, to trade at just under $0.35 on very heavy volume: Following the announcement that Vertical Designs Ltd is taking a controlling interest.